DOI: 10.69601/meandrosmdj.1851742 ISSN: 2149-9063

In Vitro Evaluation of the Antiproliferative and Wound Healing Potential of Eritadenine

Rüstem Anıl Uğan, Aylin Aydın, Şeyma Kırman
Show PDF Cite
Aim: Hepatocellular carcinoma (Hepg2) is the most prevalent liver cancer worldwide and a major cause of cancer-related mortality. Natural compounds with therapeutic value are increasingly explored as alternative strategies. Eritadenine, a bioactive component of Lentinus edodes, has demonstrated antiproliferative and pro-apoptotic activity in several cancer cell models. However, its potential wound-healing role remains unclear. This study investigated the dual effects of eritadenine on Hepg2 and L929 fibroblast cell lines.Methods: Hepg2 cells were treated with eritadenine (4×10⁻⁴–4×10⁻⁸ M) for 24, 48, and 72 hours. Cytotoxicity was determined using the MTT assay. For wound healing, confluent L929 fibroblasts underwent a scratch assay and were exposed to concentrations of 4×10⁻⁵–4×10⁻⁸ M. Wound closure was assessed microscopically at 24 and 48 hours. Only commercially sourced cell lines were used, and no animal or human experiments were conducted.Results: High-dose eritadenine (4×10⁻⁴ M) markedly reduced Hepg2 viability at 24 hours, whereas the lowest dose (4×10⁻⁸ M) enhanced proliferation at both 24 and 72 hours. Intermediate doses showed no significant changes. In fibroblasts, 4×10⁻⁶ M induced the highest wound closure, while 4×10⁻⁸ M also supported healing across both time points.Conclusion: Eritadenine displayed a dose-dependent dual effect: cytotoxic at higher concentrations and proliferative at lower ones, alongside wound-healing enhancement in fibroblasts. These findings suggest its potential in liver cancer management and tissue regeneration.Keywords: Antineoplastic agents, Eritadenine, Hepg2, L929, Wound healing.

More from our Archive